Precision BioSciences Announces FDA Acceptance Of IND For PBCAR269A, A BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate For Multiple Myeloma

-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan

Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan · 01/13/2020 12:29